title: Insulin-like growth factor 1 receptor (IGF-1R) inhibitor: another arrow in the quiver - Will it hit the moving target?
abstract: Insulin-like growth factor 1 receptor (IGF-1R) inhibitors have anti-tumor activity in various cancers. The development of IGF-1R inhibitors is a multi-dimensional and complex issue, involving many different drugs, and affecting several different points along the pathway. Matching patients with these agents based on molecular profiling/signatures will be essential for the proper development of this type of targeted agent.
authors.forename: Vivek
authors.initials: V
authors.lastname: Subbiah
authors.forename: Laura S
authors.initials: LS
authors.lastname: Angelo
authors.forename: Razelle
authors.initials: R
authors.lastname: Kurzrock
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000187:drug effects*; D015398:Signal Transduction / Q000187:drug effects*
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D007334:Insulin-Like Growth Factor I